LUCD Stock Summary and Trading Ideas (Lucid Diagnostics | NASDAQ:LUCD)

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Lucid Diagnostics trades on the NASDAQ stock market under the symbol LUCD.

As of June 18, 2026, LUCD stock price climbed to $1.08 with 4,865,891 million shares trading.

LUCD has a beta of 0.33, meaning it tends to be less sensitive to market movements. LUCD has a correlation of 0.00 to the broad based SPY ETF.

LUCD has a market cap of $206.02 million. This is considered a Small Cap stock.

Last quarter Lucid Diagnostics reported $1 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-130,400 and missed earnings estimates by -$.01.

In the last 3 years, LUCD traded as high as $25.81 and as low as $.63.

The top ETF exchange traded funds that LUCD belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWN.

LUCD has underperformed the market in the last year with a return of -14.3%, while the SPY ETF gained +26.9%. In the last 3 month period, LUCD fell short of the market, returning -19.4%, while SPY returned +13.5%. However, in the most recent 2 weeks LUCD has outperformed the stock market by returning +5.9%, while SPY returned -1.1%.

LUCD support price is $.94 and resistance is $1.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LUCD shares will trade within this expected range on the day.